Hsian-Rong Tseng,
Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute,
University of California-Los Angeles
Dr. Tseng is professor in the Department of Molecular & Medical Pharmacology at UCLA. He also holds memberships of the California NanoSystems Institute, Crump Institute for Molecular Imaging and Institute for Molecular Medicine on the UCLA campus. Since he joined UCLA Pharmacology in 2003, Dr. Tseng’s group at UCLA has developed a series of nanotechnology- and microfluidics-enabled in vitro molecular diagnostic (IVMD) technologies. In collaboration with his physician colleagues, the goal of their joint team is to translate these new IVMD technologies from research bench to clinical practice.
Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells
Thursday, 29 September 2016 at 18:00
Add to Calendar ▼2016-09-29 18:00:002016-09-29 19:00:00Europe/LondonClinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor CellsLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Circulating tumor cell (CTC) is regarded as a liquid biopsy of tumor, allowing non-invasive, repetitive, and systemic sampling of disease. Although detecting and enumerating CTCs is of prognostic significance in metastatic cancer, it is conceivable that performing molecular and functional characterization on CTCs will reveal unprecedented insight into the pathogenic mechanisms driving lethal disease. Nanomaterial-embedded cancer diagnostic platforms, i.e., NanoVelcro CTC Assays represent a unique rare-cell sorting method that enables detection isolation, and characterization of CTCs in peripheral blood, providing an opportunity to noninvasively monitor disease progression in individual cancer patients. Over the past decade, a series of NanoVelcro CTC Assays has been demonstrated for exploring the full potential of CTCs as a clinical biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling. In this presentation, Dr. Tseng will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clinical applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, kidney cancer, liver cancer, and melanoma.
Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-29 18:00:002016-09-29 19:00:00Europe/LondonClinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor CellsLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
